Helping Patients Anticipate and Manage Drug Costs

MARCH 12–13, 2020 | THE ALEXANDRIAN | ALEXANDRIA, VA
PRE READING

- The Next Frontier in Reducing Costs of Care: Patient Affordability

- The Out-of-Pocket Cost Burden for Specialty Drugs in Medicare Part D in 2019

- Assessing Drug Pricing Reform Proposals: The Real Leverage And Benefits Of Competitive Licensing

- Improving The Affordability Of Specialty Drugs By Addressing Patients' Out-Of-Pocket Spending
  https://www.healthaffairs.org/do/10.1377/hpb20180116.800715/full/

PLEASE BE ADVISED

Photographs and/or video taken during this AMCP Partnership Forum may be used in AMCP’s newsletters, website, promotions, education, and editorial content, or advertising and/or other unspecified AMCP-related materials; such images may be altered to suit various applications. By appearing in this public place, you grant AMCP unrestricted rights to use and publish photographs or video in which you may be included and release any AMCP-contracted photographer or videographer and/or their legal representatives and assigns from all claims and liability relating to said photographs and/or video.
Welcome to AMCP’s Partnership Forum, “Helping Patients Anticipate and Manage Drug Costs.” Our first Partnership Forum of 2020 underscores the ultimate goal of managed care pharmacy: To ensure patients have access to medicines they need at a cost they can afford.

Helping patients, after all, is the reason we got into this profession. And to be successful, we must place the patient at the center of the conversation as we explore both the intended and unintended consequences of the myriad drug pricing proposals now under consideration.

We must ask: How would proposed changes to rebates under federal programs affect patients? How would requirements for public disclosure and transparency of drug prices affect patients? And how would regulations changing PBM and health plan business models affect patients?

Over the next day and a half, we will examine these questions and more. We will consider implications of several common drug pricing reforms, including best practices around point-of-sale rebates and patient-assistance programs. Specifically, we will address:

- Opportunities to curb rising drug costs when approaching different reforms.
- Solutions to improve price transparency and help patients understand and manage drug costs.
- The value of patient assistance programs, and how copay policies fit into the affordability equation.
- Best practices around point-of-sale rebates, patient assistance programs, and copay coupons.
- Greater out-of-pocket cost protections for patients through benefit design.

Following this event, AMCP will produce a proceedings document of our findings and recommendations, which will be published in an upcoming issue of AMCP’s *Journal of Managed Care & Specialty Pharmacy* and widely disseminated to decision makers around the country.

Finally, I would like to thank our event sponsors: Merck, Pfizer, PhRMA, and Takeda.

I look forward to a productive Partnership Forum.

Sincerely,

Susan A. Cantrell, RPh, CAE
AMCP CEO
Clifford Goodman, PhD
Senior Vice President
The Lewin Group

Clifford Goodman, PhD, is a senior vice president at The Lewin Group. He has 30 years of experience in health technology assessment, evidence-based health care, health economics, and aspects of health care innovation, regulation, and payment. Dr. Goodman often serves as a health policy issues moderator and facilitator of expert panels and advisory boards. He served as chair of the CMS Medicare Evidence Development & Coverage Advisory Committee and president of the professional society, Health Technology Assessment International. He received his doctorate in philosophy from The Wharton School of the University of Pennsylvania and degrees from Georgia Tech and Cornell.
THURSDAY, MARCH 12

3–3:30pm  Welcome and introductions

3:30–4:15pm  Presentation: Opportunities for improving price transparency and curbing the rising cost of pharmaceuticals

4:15–4:30pm  Break

4:30–5:30pm  Panel 1: Understanding stakeholder perspectives on rising cost of pharmaceuticals

5:30–6:45pm  Breakout session #1: How to approach prescription affordability reforms

6:45pm  Reception

HOSTED BY AMCP IN PARTNERSHIP WITH

AstraZeneca  Genentech  Gilead  gsk

Johnson & Johnson  Merck  National Pharmaceutical Council

Novo Nordisk  Pfizer  Pharma Research + Progress + Hope  Sandoz  a Novartis company

Sanofi  Seattle Genetics  Takeda
# Agenda

**Friday, March 13**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>7–8am</td>
<td>Breakfast</td>
</tr>
<tr>
<td>8–8:15am</td>
<td>Welcome and day 1 debrief</td>
</tr>
<tr>
<td>8:15–9:15am</td>
<td>Panel 2: Possible solutions to improve price transparency and help patients understand and manage drug costs</td>
</tr>
<tr>
<td>9:15–9:30am</td>
<td>Break</td>
</tr>
<tr>
<td>9:30–11am</td>
<td>Breakout session #2: Value of patient assistance programs and point-of-sale rebates</td>
</tr>
<tr>
<td>11–11:45am</td>
<td>Networking lunch</td>
</tr>
<tr>
<td>11:45am–12:45pm</td>
<td>Panel 3: The future of affordability in pharmacy</td>
</tr>
<tr>
<td>12:45–1pm</td>
<td>Break</td>
</tr>
<tr>
<td>1–2:30pm</td>
<td>Breakout session #3: Ensuring greater out-of-pocket cost protection for patients through benefit design</td>
</tr>
<tr>
<td>2:30–3pm</td>
<td>Full group discussion: Next steps for AMCP and stakeholders</td>
</tr>
<tr>
<td>3pm</td>
<td>Forum summary and conclusions</td>
</tr>
</tbody>
</table>
Melissa Andel, MPP
Vice President of Health Policy
Applied Policy

Melissa Andel, MPP, is the vice president of health policy at Applied Policy. She has more than 15 years of health policy experience with the pharmacy and managed care industries. At Applied Policy, Melissa manages the pharmaceutical manufacturer portfolio for the firm, helping clients solve market access problems for existing products, and working with brand teams prior to launch to identify opportunities and potential challenges. She also assists clients in understanding changes in federal health policy, particularly related to Medicare, Medicaid, and the Affordable Care Act, and how those changes may impact them and the patients they serve.

Amanda Bain, PharmD, MPH, MBA
Director, Pharmacy and Care Management
The Ohio State University Health Plan Inc.

Amanda Bain, PharmD, MPH, MBA, is the director of pharmacy and care management for The Ohio State University Health Plan. In her role, she is responsible for design, implementation, and evaluation of pharmacy benefits, information systems, and clinical programs created to impact population health. Dr. Bain supervises pharmacists and nurses in medication therapy management, disease management, care coordination, enhanced case management, and utilization management. She is also the director for the managed care pharmacy residency at The Ohio State University and has served on numerous national committees regarding pharmacy education, initiatives, quality, and technology.

Harold Carter, PharmD
VP, Pharma Strategy & Contracting
Express Scripts

Harold Carter, PharmD, is responsible for leading medical pharma contracting and drug procurement strategy. Prior to his current role, Dr. Carter held numerous roles across the organization, including strategic development and management of Express Scripts’ Value Based Solutions and Generic Strategy as well as strategic development of Express Scripts’ Advanced Utilization Management Solutions. In addition to his work at Express Scripts, Dr. Carter serves on the advisory council for the Midwest CEPAC group for the Institute for Clinical and Economic Review. He also serves as a lecturer at the local pharmacy schools in St. Louis for topics surrounding managed care. Dr. Carter graduated from St. Louis College of Pharmacy with his doctorate in pharmacy.
HELPING PATIENTS ANTICIPATE AND MANAGE DRUG COSTS

PARTICIPANTS

Michelle Chang, PharmD, MBA
Director
CVS Health

Michelle Chang, PharmD, MBA, is a director with CVS Health in the Clinical Account Services Department supporting health plans. She joined CVS Health in 2011 and has experience supporting commercial, exchanges, Medicaid, and Medicare plans. Her team partners with clients on developing and executing clinical strategies, cost management strategies, pipeline and P&T Committee support, and clinical programs. She graduated from the University of California, Berkeley with a Bachelor of Science. She then pursued her Doctor of Pharmacy degree and master in business administration at the University of Maryland, Baltimore School of Pharmacy and the University of Baltimore, Merrick School of Business.

Erin Darling
Associate Vice President and Counsel, Federal Policy and Government Relations
Merck

Erin Darling currently serves as an associate vice president of federal policy for Merck. She’s responsible for leading the company’s U.S. policy team, which develops and implements advocacy and policy strategies on federal health care legislative and regulatory issues. She works extensively on Medicare, Medicaid, and other federal program coverage and payment issues, health care reform, transparency, issues related to the infectious disease and oncology franchises, and various other health care issues. Before coming to Merck in 2007, Erin worked in private practice as a health care lawyer with two Washington, D.C. law firms. Erin has a Juris Doctor, cum laude, from Georgetown University Law Center and a Bachelor in Arts in Political Science with distinction from the University of North Carolina at Chapel Hill.

Bruce Feinberg, DO
Vice President and Chief Medical Officer
Cardinal Health

Bruce Feinberg, DO, is vice president, clinical affairs and chief medical officer for Cardinal Health Specialty Solutions. He is nationally recognized for his expertise in specialty oncology and the business of specialty health care. Dr. Feinberg has been instrumental in the development of clinical pathways that aim to control costs, improve quality, and increase predictability, all of which are key factors in developing a sustainable approach for caring for patients with high-cost diseases. A highly sought-after researcher and speaker on health care policy, value-based care, and cancer, Dr. Feinberg has more than 200 publications in peer-review. He’s also the author of the bestselling Breast Cancer Answers and its follow-up book, Colon Cancer Answers.
HELPING PATIENTS ANTICIPATE AND MANAGE DRUG COSTS

PARTICIPANTS

Stephanie Forbes, PharmD
Clinical Operations Pharmacist
SinfoniaRx

Stephanie Forbes, PharmD, is a clinical operations pharmacist at SinfoniaRx. She oversees and builds client programs to improve patient outcomes and impact quality measures. She’s the former director of the Medication Management Center, one of the six clinical telehealth centers providing medication therapy management services for SinfoniaRx. She obtained her Doctor of Pharmacy degree at the University of Arizona College of Pharmacy in 2012 and has worked in MTM since 2010.

Eric Gascho
Vice President, Policy and Government Affairs
National Health Council (NHC)

Eric Gascho is the vice president, policy and government affairs of the NHC. He has been with the NHC since August 2009. In his role, Eric helps the NHC and its member organizations develop policy positions that seek to improve the lives of people with chronic diseases and disabilities and advocates for these policies on Capitol Hill and within the executive branch. Prior to joining the NHC, he worked in the government relations department of the Society of Teachers of Family Medicine. Eric earned Bachelor of Art degrees in government and business management from the University of Redlands in California.

Stephen George, PharmD, MS
Senior Consultant
Milliman

Stephen George, PharmD, MS, is a pharmacist with 20 years of experience. He serves as a senior consultant assisting clients in health care plan pharmacy operations, management of physician-administered and specialty drugs, integration of pharmacy and medical outcomes analysis, and developing ROI evaluations on medical interventions. Dr. George has experience in managed care, hospital, care management, and clinical trials. He has experience with health policy analysis, pharmacoeconomics and outcomes research, auditing PBM/specialty pharmacy contracts, 340-B pricing models, implementing disease management models, drug/device pricing, assessing pharmacy MTM programs, and developing “best-in-class” clinical applications.
Denise Giambalvo joined the Midwest Business Group on Health in 2018 as vice president and manages the coordination and marketing of monthly educational programs, social media, newsletters and employer benchmarking surveys. In addition, Denise leads various sponsor and grant-funded projects, including the National Employer Initiative on Specialty Drugs and oversees financial-related activities and annual audits. Denise has team-collaborated with stakeholders on research and pilot programs including limited-fill, site-of-service, mental and behavioral health, and data analysis. Educational activities have focused on population health management, value-based benefit design, pain management, and analytics. She currently serves on the Management and Implementation Committee for the Institute of Medicine of Chicago.

Sean Godar, PhD, MBA, is the director and team lead of analytics and employer solutions at Employers Health, a nonprofit professional benefits organization. Dr. Godar works with team members to identify client pain points and create effective strategies and recommendations to optimize firm product and service portfolios, strengthen organizational value, and enhance client experience. Prior to Employers Health, Dr. Godar was a research professor in the Department of Pharmacology and Toxicology at the University of Utah, where he researched the role of early-life stress in mental health, leading to 28 publications in high-impact, peer-reviewed scientific journals. Dr. Godar received his doctorate of philosophy in Pharmacology and Toxicology at the University of Southern California and his master of business administration from the Fuqua School of Business at Duke University.

Josh Golden has 20 years of experience as a strategic thought leader within the health care industry. He brings to bear a keen understanding of the entire pharmacy benefits supply chain to help plan sponsors optimize financial and health care outcomes for the populations that they cover. Josh is frequently called upon for speaking engagements and media inquiries at a national level. As senior vice president of strategy for Capital Rx, Josh assesses market trends, evaluates business initiatives, and develops strategic partnerships to support the continued growth of the organization.
Helping Patients Anticipate and Manage Drug Costs

Participants

Dorothy Hoffman, MPP
Access Innovation Lead
Pfizer

Dorothy Hoffman, MPP, serves as access innovation lead in Pfizer’s Healthcare Innovation Center and is responsible for creating new reimbursement, affordability, and patient engagement models in partnership with payers, PBMs, hospitals, health tech companies, and patient groups. She develops solutions to address social determinants of health. Previously, Dorothy was vice president of prescription drug policy at UnitedHealth Group. Dorothy implemented OptumRx and UnitedHealthcare’s pharmacy care services transformation and growth initiative with federal and state audiences, including predicting emerging customer needs, developing innovative solutions, utilizing ORx assets and capabilities, and advancing business development opportunities. At Lilly, Dorothy led the development of innovative partnerships with payers and PBMs focused on value-based arrangements, pre-approval communications, and patient affordability. In addition, she led Lilly’s U.S. Policy team. Dorothy has a Master in Public Policy.

Joe Honcz, RPh, MBA
Principal
C4i

Joe Honcz, RPh, MBA, has worked in the insurance, managed care/PBM and pharmaceutical consulting industries for more than two decades. Joe brings a wealth of knowledge in the clinical cost of care, product development, and innovation arenas. As a leader in pharmaceutical and health care, he harnesses insights from his payer experience and pairs it with expert analysis to differentiate client’s medical innovation across the access and reimbursement continuum.

Scott Howell, DO, MPH&TM, CPE
Physician
AIDS Healthcare Foundation

Scott Howell, DO, MPH&TM, CPE, has been in various executive positions within health plans, delegated medical groups, direct-care delivery and health care policy for the past 30 years with multiple entrepreneurial endeavors. Dr. Howell is board certified in family practice, preventative medicine and public health and addiction medicine with a master in economics from the University of Miami, master in public health and tropical medicine from Tulane University, and a master in business administration from California State University Fresno. Dr. Howell has served in the military for 25 years and his last assignment was with the Office of Secretary of Defense at the Department of Defense Inspector General, concentrating on the Wounded Warrior Program, BioAssurity, and Ebola Outbreak Assessment. Dr. Howell has published peer-reviewed articles in finance and medicine.
HELPING PATIENTS ANTICIPATE AND MANAGE DRUG COSTS

PARTICIPANTS

George Huntley
President
National Diabetes Volunteer Leadership Council

George Huntley is president of the National Diabetes Volunteer Leadership Council, a 501(c)(3) patient advocacy organization committed to securing effective, affordable health care and a discrimination-free environment for every person affected by diabetes. George served as the national chair of the board of the American Diabetes Association (ADA) in 2009. He led the ADA’s Task Force on Health Care Reform in 2008 and chaired the Legislative and Regulatory subcommittee from 2011-2015, which establishes the advocacy priorities the ADA. George has been living with Type 1 diabetes since 1983 and is currently the COO and CFO of Theoris Group Inc., an Indianapolis-based professional services firm.

Anna Hyde
Vice President of Advocacy and Access
Arthritis Foundation

Anna Hyde is the vice president of advocacy and access at the Arthritis Foundation. She oversees the federal and state legislative programs, in addition to grassroots engagement. She raises the visibility of arthritis as a public health priority; builds support for federal and state legislation that ensures access to affordable, high-quality health care; and enhances patient engagement in the policymaking process. Anna previously served as senior director of advocacy and access, managing the federal affairs portfolio and overseeing the state advocacy team. Prior, Anna was the senior manager for federal affairs at the American Congress of Obstetricians and Gynecologists and managed appropriations, physician workforce, and health IT. Anna received a Bachelor of Arts in History from Southern Methodist University and a Master in Arts in Political Science from American University.

Clint Ivie, PharmD, MBA, CSP
Specialty Pharmacy Manager
Intermountain Healthcare

Clint Ivie, PharmD, MBA, CSP, is the manager of the Intermountain Specialty Pharmacy and has been a pharmacist for nearly 10 years. He graduated with his doctorate of pharmacy from the University of Iowa and later received his master of business of administration from Western Governors University. He began his career at Target/CVS before taking the role of clinical pharmacist at Intermountain. Shortly after being hired, he transitioned to the manager position and has helped oversee the pharmacies consistent growth for nearly four years. Clint has gone on to receive National Association of Specialty Pharmacy board certification as a specialty pharmacist.
HELPING PATIENTS ANTICIPATE AND MANAGE DRUG COSTS

PARTICIPANTS

Manjula Jayabalan, PharmD, MBA
Clinical Pharmacist Account Manager
Magellan Rx Management

Manjula Jayabalan, PharmD, MBA, is a clinical pharmacist account manager at Magellan Rx Management. She is involved in the development of clinical programs and provides consultative services to commercial clients. Her responsibilities span multiple areas including clinical, product development, pricing and contracting, sales, account management, marketing and government affairs. Previously, Dr. Jayabalan gained experience drafting pricing contracts, completing requests for proposals, and working with key clients at Blue Cross Blue Shield of Michigan. She earned her doctorate of pharmacy from Lipscomb University and a master of business administration from the University of the Sciences. She completed her residency at BlueCross BlueShield of Tennessee.

Kollet Koulianos, MBA
Senior Director Payer Relations
National Hemophilia Foundation (NHF)

Kollet Koulianos, MBA, is responsible for project leadership, analysis, and development of NHF’s health care payer education strategies, policies and programs, including the Comprehensive Care Sustainability Collaborative. Prior to her tenure at NHF, Kollet served as the executive director of the Bleeding & Clotting Disorders Institute in Peoria, IL, a federally recognized Hemophilia Treatment Center of Excellence. With hemophilia ranking 12 of 20 for highest cost catastrophic claims, ninth among stop loss carriers, and reported eight of 10 highest cost claims among jumbo employer-sponsored health plans, Kollet strongly believes that the stage is set for all parties who share in the cost risks associated with rare chronic disorders to enter into meaningful dialogue with those that are the experts in managing each specific high-cost claimant population.

Dana McCormick, RPh, FAMCP
Director Pharmacy
Blue Cross Blue Shield Texas

Dana McCormick, RPh, FAMCP, is currently with Blue Cross Blue Shield of Texas (BCBSTX) as director of pharmacy clinical account consulting. Prior to joining BCBSTX, she was with Sanofi and spent time in both managed care account management and medical affairs. Dana has spent her entire professional career in managed care with experience also including PBM and health plan association work. She has been very active in AMCP at the national and Affiliate levels and is a past president of the board of directors.
HELPING PATIENTS ANTICIPATE AND MANAGE DRUG COSTS

PARTICIPANTS

Jennifer Meece, MD
Medical Director, Indiana Medicaid
Anthem

Jennifer Meece, MD, is a medical director for Anthem Indiana Medicaid. She’s a graduate of Vanderbilt University and Indiana University School of Medicine. Dr. Meece started her internal medicine career as a physician in the United States Army. She completed her residency training at Tripler Army Medical Center in Honolulu and served as a Medical Corps officer for seven years. Dr. Meece then practiced academic internal medicine at Northwestern University’s Feinberg School of Medicine and Indiana University Health prior to joining Anthem.

Jamie Miller, RPh
System Director, Managed Care Pharmacy Services
Geisinger Health Plan

Jamie Miller, RPh, is the system director of managed care pharmacy services for Geisinger Health Plan in Danville, Pa. She oversees the clinical and operational services of all pharmacy functions at the health plan, which serves approximately 560,000 members. Jamie has been with Geisinger since 2011. During her tenure as director with the pharmacy department, she along with her team have implemented many changes including a new Medicaid line of business; an electronic prior authorization system; and new retail, mail order, and specialty networks. She received her pharmacy degree from Duquesne University.

Amy Niles
Executive Vice President
Patient Access Network (PAN) Foundation

Amy Niles oversees PAN Foundation’s relations and partnerships with the patient advocacy community and leads its public policy and advocacy initiatives. Before joining the PAN Foundation, Amy served for eight years as chair, medical relations and advocacy for the Together Rx Access program. Prior, she was president and CEO of the National Women’s Health Resource Center, now known as Healthy Women, for more than a decade. Amy has a master of business administration from Baruch College, City University of New York, and an undergraduate degree in Biology from the University of Rochester.
HELPING PATIENTS ANTICIPATE AND MANAGE DRUG COSTS

PARTICIPANTS

Heather Odem, PharmD
Director of Pharmacy - Government Programs Mississippi
UnitedHealthcare

Heather Odem, PharmD, is the director of pharmacy for UnitedHealthcare Government Programs in Mississippi. In this position she’s responsible for pharmacy financial and utilization trend monitoring and management, interfacing with state and other regulatory bodies, and managing relationships with OptumRx. Dr. Odem has more than 10 years of experience in the pharmacy industry. Her background includes district management in the retail pharmacy setting as well managed care. Dr. Odem holds a Bachelor of Science in Pharmacology from the University of California Santa Barbara and a Doctor of Pharmacy from University of the Pacific in California. Dr. Odem is a registered pharmacist, licensed by California and Mississippi.

Swati Patel, PharmD, MBA
Managing Director
Deloitte Consulting

Swati Patel, PharmD, MBA, is a leader in the Deloitte Consulting’s Healthcare and Life Sciences practice focused on supply chain optimization. Dr. Patel has more than 15 years of experience leveraging a pharmacy background to assist health systems with sustainable margin and performance improvement transformations. She has assisted more than 80 clients achieving expense management, implementing technology, evaluating productivity and maximizing revenue cycle. Her expertise includes 340B and pharmacy practice optimization. She has leveraged her breadth of pharmacy experience for clients in the pharmaceutical industry, pharmacy benefits management, distributors, and retail pharmacy chains. Dr. Patel’s full range of pharmacy capabilities allows her to provide end-to-end drug supply chain solutions.

Michelle Rice
Chief External Affairs Officer
National Hemophilia Foundation (NHF)

Michelle Rice is responsible for the strategic development, implementation, and oversight of NHF’s public policy agenda, capacity building initiatives, and building key external partnerships with constituencies and health care leaders. Previously, she served as the executive director of Hemophilia of Indiana, where she influenced critical health care policy decisions impacting the hemophilia community. As the mother of two sons with severe hemophilia, Michelle has more than 28 years advocating and leading change in various roles, including board positions with the Indiana Comprehensive Health Insurance Association, the Foundation for Complex Healthcare Solutions, and Community Health Charities. Michelle facilitated dialogue and collaboration between payers and providers that led to the conceptualization and implementation of the Comprehensive Care Sustainability Collaborative (CCSC). The CCSC is now being recognized by other national patient advocacy organizations.
HELPING PATIENTS ANTICIPATE AND MANAGE DRUG COSTS

PARTICIPANTS

Annie Schuster, PharmD
Senior Director, Government Pharmacy Clinical Programs
Cigna

Annie Schuster, PharmD, is responsible for the Cigna Medicare and Medicaid clinical pharmacy programs including formulary and specialty drug strategy and pharmacy quality improvement programs to optimize medication therapy. She’s involved in Cigna’s government advocacy efforts regarding affordability. Dr. Schuster has 15 years of experience in the health care industry and is the residency program director for the Cigna PGY1 Managed Care Pharmacy Residency Program. She currently serves as chair of the AMCP Professional Practice Committee. Annie received her doctorate of pharmacy from the University of Illinois at Chicago.

Patrick Stone
Vice President, Government Relations and Advocacy
National Psoriasis Foundation (NPF)

Patrick Stone joined the NPF in 2014 with a decade of government relations experience, including consulting with a fifty-state government relations firm and serving as staff in the Maryland State Legislature. In his current role, he oversees all federal and state advocacy activities for the organization. Prior to taking on his current role, he created and led the NPF state government relations team. He has a Bachelor of Political Science from Towson University.

Michael Turchetti, MPP
Director, Policy and Research
Pharmaceutical Research and Manufacturers of America (PhRMA)

Michael Turchetti, MPP, is the director of policy and research at PhRMA and works on policy issues related to commercial insurance, benefit design, and patient access. Michael is passionate about how the policy environment impacts health care business decisions and patient access to health care. Prior to PhRMA, Michael worked at Booz Allen Hamilton and the Lewin Group where he analyzed CMS and state Medicaid agency programs. Michael is currently the events director for the D.C. Society of Young Health Policy Professionals. He received his Master of Public Policy from the Schar School of Policy and Government at George Mason University and his Bachelor of Arts in Psychology from American University.
Robin Turpin, PhD is the value-evidence and health outcomes scientific lead at Takeda Pharmaceuticals, USA. She received her doctorate of philosophy in Applied Social Psychology from Loyola University Chicago and was a distinguished fellow with the National Institute of Disability and Rehabilitation Research. Dr. Turpin worked in health services and outcomes research for hospital and health care systems, including a period with the Joint Commission on Accreditation of Healthcare Organizations to lead reliability and validity testing for performance metrics. She's held HEOR positions with Merck, Baxter, and Takeda. She's co-authored more than 100 books, book chapters, and journal articles on health economics, health behavior, and population health management. She's won awards from AMCP, ASHP, ISPOR, the Joint Commission, and the Disease Management Association of America for her research.
Thank You
To our distinguished participants and guests.

About AMCP
AMCP is the professional association leading the way to help patients get the medications they need at a cost they can afford. AMCP’s diverse membership of pharmacists, physicians, nurses, and professionals in life sciences and biopharmaceutical companies leverage their specialized expertise in clinical evidence and economics to optimize medication benefit design and population health management, and help patients access cost-effective and safe medications and other therapies. AMCP members improve the lives of nearly 300 million Americans served by private and public health plans, pharmacy benefit management firms, and emerging care models.

AMCP Mission
To improve patient health by ensuring access to high-quality, cost-effective medications and other therapies.
Findings and recommendations from this event will be published in an upcoming issue of AMCP’s *Journal of Managed Care & Specialty Pharmacy* and will be widely disseminated to decision makers around the country.